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Atheroembolic renal disease
Francesco Scolari, Pietro Ravani
Atheroembolic renal disease develops when atheromatous aortic plaques rupture, releasing cholesterol crystals into 
the small renal arteries. Embolisation often aﬀ ects other organs, such as the skin, gastrointestinal system, and brain. 
Although the disease can develop spontaneously, it usually develops after vascular surgery, catheterisation, or 
anticoagulation. The systemic nature of atheroembolism makes diagnosis diﬃ  cult. The classic triad of a precipitating 
event, acute or subacute renal failure, and skin lesions, are strongly suggestive of the disorder. Eosinophilia further 
supports the diagnosis, usually conﬁ rmed by biopsy of an aﬀ ected organ or by the fundoscopic ﬁ nding of cholesterol 
crystals in the retinal circulation. Renal and patient prognosis are poor. Treatment is mostly preventive, based on 
avoidance of further precipitating factors, and symptomatic, aimed to the optimum treatment of hypertension and 
cardiac and renal failure. Statins, which stabilise atherosclerotic plaques, should be oﬀ ered to all patients. Steroids 
might have a role in acute or subacute progressive forms with systemic inﬂ ammation.
Introduction
Atheroembolic renal disease, sometimes referred to as 
renal cholesterol crystal embolisation, is a form of renal 
failure that is secondary to occlusion of renal arteries, 
arterioles, and glomerular capillaries with cholesterol 
crystals originating from atheromatous plaques of the 
aorta and other major arteries. Atheromatous material can 
be dislodged spontaneously or after intravascular trauma 
or anticoagulation. Typically, embolisation aﬀ ects the 
kidneys, skin, gastrointestinal system, and brain. For this 
reason, atheroembolic renal disease is regarded as part of 
a multisystemic disorder.1–5 Athero embolic disease, like 
thromboembolism, can complicate severe atherosclerosis. 
However, thrombo embolism develops when a thrombus 
overlying an ulcerated plaque embolises and lodges in 
medium or large arteries, causing localised ischaemia. 
Panum6 ﬁ rst described atheroembolism in 1862, in the 
autopsy report of the Danish sculptor, Thorwaldsen, who 
died from a heart attack. In a coronary artery, a ruptured 
atheroma was identiﬁ ed, with atheromatous material 
ﬁ lling the lumen distally. In English records, the ﬁ rst 
report of atheroembolism was made in 1926 by Benson,7 
who reviewed three cases of coronary embolisation. In 
1945, Flory1 proved the embolic origin of cholesterol 
crystals from eroded aortic atheromatous plaques. 40 years 
later, Fine and co-workers4 reviewed 221 cases of cholesterol 
crystal embolisation, underlining the low rate of 
antemortem clinical diagnosis. In the past two decades, 
atheroembolic renal disease has changed from being a 
pathological curiosity to a clinical syndrome. Some 
studies8–12 provided an accurate assessment of the main 
characteristics of the disorder, including risk factors, causal 
events, clinical and laboratory ﬁ ndings, and renal and 
patient outcomes. Thus, this disease can now be thought 
of as a recognisable cause of renal disease, with diagnosis 
before death possible in most cases.
Epidemiology
Atheroembolic renal disease complicates widespread 
atherosclerosis in adults older than 60 years.8–12 The 
disorder predominantly aﬀ ects men and is rare in black 
people, possibly because of decreased recognition of the 
cutaneous lesions.13 Incidence is unknown. In clinical 
series, prevalence varies, probably because of sampling 
bias. In unselected autopsy series,14–17 the frequency of 
atheroemboli ﬁ ndings is low, ranging from 0·31% to 
2·40%. However, in autopsy studies2,16–19 done in elderly 
patients and those who died after aortic surgery or 
aortography, researchers have reported an increased 
frequency, from 12% to 77%. In two large renal biopsy 
studies,20,21 frequency of 1% was reported. However, in 
people older than age 60 years, the prevalence was 
4·0–6·5%.22,23 In clinical practice, Mayo and Swartz9 have 
estimated that 5–10% of all cases of acute renal failure 
could be due to atheroembolism.9 Belenfant and 
colleagues10 reported that 3% of patients admitted to a 
tertiary renal intensive care unit were diagnosed with 
atheroembolic renal disease.10
Pathophysiology
Presence of diﬀ use aortic atherosclerosis is essential for 
development of atheroembolic renal disease.1–3 The 
usual risk factors for atherosclerosis (age older than 
60 years, male sex, diabetes, hypertension, and cigarette 
smoking) are also major risk factors for atheroembolic 
renal disease11,24,25 (panel 1). The atherosclerotic plaque, 
which is the main pathological entity of atherosclerosis, 
Search strategy and selection criteria
We searched Medline (January, 1950–July, 2009), the Cochrane 
Library (January, 1993–July, 2009), and Embase (January, 
1966–July, 2009) with the search terms “atheromatous 
embolism”, “athero-embolism”, “atheroembolism”, 
“cholesterol crystals”, “cholesterol embolism”, “cholesterol 
embolization”, or “cholesterol emboli”. We also searched for 
these terms combined with “clinical trials”, “prevention”, 
“pathogenesis”, “pathophysiology”, “diagnosis”, and 
“epidemiology”. We had no language restrictions. We focused 
on original research, systematic reviews, and reviews or 
editorials. We also searched the reference lists of selected 
articles identiﬁ ed by the search strategy. The date of the last 
search was July 31, 2009. 
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is characterised by a ﬁ brous cap overlying a core 
containing necrotic cellular debris, foam cells, and 
lipids, including cholesterol crystals. Haemodynamic 
stress, inﬂ ammation, and haemorrhage can destabilise 
the plaque, which becomes friable and prone to erosion 
and rupture.26 The disease develops when the ﬁ brous 
cap is denuded and portions of its core components 
break oﬀ , reaching the arterial bloodstream.1–5 Plaque 
disruption caused by shear stress or intrinsic 
mechanisms leads to spontaneous atheroembolism—
the most common form in the 1980s.4 
Nowadays, atheroembolic renal disease tends to be 
iatrogenic, accounting for as many as 76–77% of cases in 
recent series,10–12,27,28 suggestive of the increased use of 
vascular procedures, anticoagulation, or thrombolysis4,11,24 
(table 1). Thurlbeck and Castleman2 ﬁ rst recognised 
embolisation as a complication of vascular surgery 
causing plaque disruption during vessel incisions, 
cannulation, manual manipulation, or clamping. 
Embolisation can develop with any vascular procedure, 
such as abdominal aortic aneurysm resection and 
endovascular surgery, and aortoiliac, aortofemoral, and 
coronary artery bypass surgery.11,24 Angiography is the 
most common iatrogenic cause, accounting for up to 
80% of cases.8,10,27 The disorder has been reported after 
aortography, renal, mesenteric, or coronary angiography, 
and percutaneous transluminal angioplasty with and 
without stenting. Mechanical trauma has a key role. 
Guidewires and catheters can scrape aortic walls and 
disrupt atherosclerotic plaques. 
Coronary angiography is the most common procedure 
causing embolism.24,27 However, the risk associated with 
coronary angiography might be underestimated in some 
study designs. Large retrospective studies reported 
incidence rates of one to two new cases per 
1000 procedure-years.15,29,30 Conversely, incidence of the 
disease after coronary angiography was several times 
higher than this rate, at 18–24 new cases per 
1000 procedure-years in two prospective studies.31,32 
Failure to search systematically for the disease in 
retrospective studies might be one possible explanation 
for this discrepancy. Since use of angiographic and 
endovascular procedures has increased exponentially 
during the past decades, and these procedures are now 
liberally extended to patients older than 60 years and with 
increasingly severe disease, the frequency of 
atheroembolic renal disease could reasonably be expected 
to rise in patients at risk. 
Atheroembolic renal disease is an uncommon 
complication that is reported in patients given anti–
coagulants (warfarin, heparin, and low-molecular-weight 
heparin) or after thrombolytic therapy.3–5,8–12 These 
therapies can undermine the stabilising protective eﬀ ects 
of thrombi on ulcerated plaques.33–36 In studies of patients 
with biopsy-proven atheroembolic renal disease, 
anticoagulation was regarded as a precipitating factor in 
13–76% of cases.4,5,8–12 However, in the absence of 
preceding invasive vascular procedures, anticoagulation 
was the sole triggering factor in only 7% of patients.
Once in the bloodstream, emboli lodge in small arteries 
of 150–200 mm in diameter.1–4 In studies20,21,37–40 in people 
and animals, results suggest that emboli produce a 
microcrystalline angiitis, characterised by an endothelial 
inﬂ ammatory reaction developing in a stepwise pattern. 
Shortly after lodging, polymorpho–nuclear leukocytes 
and esosinophils inﬁ ltrate the aﬀ ected arterioles, 
preceding mononuclear-cell inﬁ ltration and giant-cell 
formation. Thrombus formation then takes place, with 
endothelial proliferation and intimal ﬁ brosis, leading to 
arterial obstruction. This ﬁ nal late phase occurs within 
2–4 weeks. These processes generally result in ischaemia, 
sometimes in infarction, and rarely in necrosis. Because 
the crystals are insoluble in body ﬂ uids and not removable 
by phagocytosis, they persist indeﬁ nitely. 
Histologically, cholesterol crystal emboli are identiﬁ ed 
in the lumen of arcuate and interlobular arteries as 
biconvex, needle-shaped, and empty clefts, referred to as 
ghost cells, because they dissolve during specimen 
processing. Rarely, small crystals lodge in the aﬀ erent 
arterioles and glomerular capillaries. The tissue damage 
caused by these crystal emboli is usually patchy. 
Glomerular and interstitial changes are mainly ischaemic, 
with a varying extent of glomerular obsolescence and 
interstitial ﬁ brosis. In the early phases, areas of acute 
tubular necrosis can be identiﬁ ed. Cholesterol crystal 
Panel 1: Population at risk for atheroembolic renal disease
• Male sex
• Older than age 60 years
• White people
• Hypertension
• Tobacco use
• Diabetes mellitus
• Atherosclerotic vascular disease
• Ischaemic cardiac disease
• Cerebrovascular disease
• Abdominal aortic aneurysm
• Peripheral vascular disease
• Ischaemic nephropathy
n Spontaneous AERD (%) Iatrogenic AERD
All causes 
(%)
Angiography 
(%)
CV surgery 
(%)
Anticoagulation 
(%)
Fine4 221 153 (69%) 68 (31%) 39 (18%) 20 (9%) 30 (14%)
Lye5 129 50 (40%) 79 (60%) 55 (43%) 7 (5%) 17 (13%)
Thadhani8 52 0 (0%) 52 (100%) 50 (96%) 2 (41%) 19 (37%)
Belenfant10 67 3 (4%) 64 (96%) 57 (85%) 24 (36%) 51 (76%)
Scolari27 354 83 (24%) 271 (76%) 221 (81%) 69 (25%) 108 (40%)
AERD=atheroembolic renal disease. CV=cardiovascular.
Table 1: Precipitating factors of atheroembolic renal disease
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emboli are also identiﬁ ed in the skin, gastrointestinal 
tract, and muscle11,20,21 (ﬁ gures 1 and 2). 
Clinical features
Clinical presentation of atheroembolic renal disease 
depends on the location and size of the embolising 
plaque, lodging sites, intensity and recurrence of the 
showering process, and pre-existing atherosclerotic 
disease. The ascending aorta and proximal aortic arch 
are the major sources of emboli to the cerebral and 
retinal arteries. Emboli to the visceral and renal arteries 
and to arteries of the legs and feet come from the 
descending thoracic and abdominal aorta.1–4 Subclinical 
or mild episodes can go completely unrecognised. 
However, massive embolisation can lead to a fulminant 
clinical picture, with multi-system involvement. 8–12 
(panel 2, table 2).
Kidney function can be aﬀ ected acutely, subacutely, or 
in a chronic but slow, progressive way.8–12,24,25 A pronounced 
renal impairment with acute onset, arising within 1 week 
of a clear causal event, aﬀ ects 20–30% of patients.24,27 This 
abrupt renal impairment is due to massive migration of 
crystals, and is associated with evidence of embolisation 
elsewhere, aﬀ ecting gastrointestinal and cutaneous 
systems in most cases. The most common form of 
atheroembolic renal disease is a subacute presentation, 
with progressive renal failure developing in a stepwise 
way during several weeks after an inciting event. Frock 
and co-workers41 reported that the mean interval between 
the arteriographic procedure and diagnosis of disease 
was 5·3 weeks.41 This long delay between the triggering 
event and the onset of renal insuﬃ  ciency suggests a 
causal role of recurrent emboli showers and inﬂ ammatory 
endothelial reaction. Another presentation is a chronic, 
slowly progressive renal impairment, often ascribed to 
nephroangiosclerosis or ischaemic nephropathy, which 
frequently co-cluster with cholesterol emboli. This mild 
form, with low-grade, clinically silent crystal migration is 
frequently underdiagnosed because extrarenal signs are 
absent and renal biopsy samples are not taken.42
Figure 1: Renal cholesterol crystal emboli 
Intraglomerular cholesterol crystals (arrows, A–B); cholesterol crystals in a renal arteriole (C); crystals in an arcuate artery with a pseudovasculitis inﬂ ammatory 
reaction (arrow, D); crystals in an arcuate artery, and encasement of a crystal by a giant cell (arrow, E); and organised occlusive crystals in a renal arteriole (F). 
A 
D E F 
B C 
100 μM
50 μM
50 μM 500 μM
100 μM
100 μM
Figure 2: Cholesterol crystal emboli in derma arterioles
Low-power view of cholesterol crystals (arrow, A); and high-power showing clusters of cholesterol crystals (B–D).
A B 
C D 
500 μM
50 μM
100 μM
100 μM
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The clinical course of renal failure can be variable. 
Dialysis is needed in 28–61% of patients with acute or 
subacute disease, with 20–30% partly recovering kidney 
function after a variable period of dialytic support.8–12 
Recovery can be due to reversal of inﬂ ammation and 
resolution of concurrent acute tubular necrosis in 
ischaemic areas. Finally, atheroembolic renal disease can 
be associated with severe, uncontrolled hypertension. 
Renal infarction is a rare ﬁ nding.20,21 
 Skin lesions are the most common extrarenal 
manifestations. Incidence of skin lesions is about 35%.43 
However, in most recent studies,8–12,44–46 the frequency 
ranged from 75% to 96%. The classic skin lesions of this 
disease are blue toe syndrome and livedo reticularis. 
Aﬀ ected toes are blue, cyanotic, painful, and cool to 
touch. The lesion might progress to ulceration, digital 
infarcts, or gangrene needing amputation. Patients often 
have palpable distal pulses. Livedo reticularis is a net-
like, mottled red-blue discolouration usually on the lower 
legs and feet but sometimes on the buttocks and trunk. 
Blue toes and livedo reticularis are most evident on 
physical examination when the patient is upright. Rarely, 
the skin lesions are erythematous painful nodules or 
palpable purpura, requiring exclusion of leukocytoclastic 
vasculitis44–46 (ﬁ gure 3). 
The gastrointestinal system is the third most often 
aﬀ ected system (18–48% of patients), leading to substantial 
morbidity.8–12 Gastrointestinal tract involvement can take 
many forms. Patients can develop symptoms such as occult 
or frank blood loss and abdominal pain. Bleeding originates 
from any site, including the stomach, and results from 
superﬁ cial mucosal ulcerations or infarcts. Abdominal pain 
is caused by ischaemia of the bowel wall, potentially creating 
malabsorption and diarrhoea. Frank bowel infarction and 
perforation usually arise in the setting of catastrophic multi-
organ disease. The liver, gallbladder, and pancreas are less 
commonly aﬀ ected.47–51 Gastrointestinal eﬀ ects are often 
overlooked. Diagnosis can be established by pathological 
examination, because the endoscopic appearance is non-
speciﬁ c.52 Patient outcomes in the presence of gastro-
intestinal disease are very poor.24,27
The true incidence of neurological embolisation is 
unknown and diﬃ  cult to estimate, because the deﬁ nitive 
diagnosis depends on evidence of embolisation to other 
organs. In the largest studies, neurological manifestations 
occurred in 4–23% of the patients with atheroembolic 
renal disease.8–12,27 Mental confusion, transient ischaemic 
attack, focal neurological deﬁ cits, and amaurosis fugax 
are common ﬁ ndings.53–55 Retinal emboli can aﬀ ect 
6–25% of patients,56 representing a key to diagnosis 
(ﬁ gure 4).8–12 Rarely, spinal cord infarction with leg 
paralysis develops.57–60
Myositis and splenic infarcts are rare manifestations.61 
Emboli deriving from the aortic root or the proximal 
segments of the coronary arteries are often associated with 
angina and sudden cardiac death.62,63 Pulmonary 
involvement proven by biopsy sample, characterised by 
diﬀ use alveolar haemorrhage mimicking systemic 
vasculitis, has been described in a few patients. The 
pathogenetic mechanisms of pulmonary haemorrhage 
remain poorly understood—a local inﬂ ammatory reaction 
elicited by emboli might have a role.64–67 In autopsy studies, 
subclinical involvement of adrenals, testes, prostate, 
Panel 2: Clinical manifestations of atheroembolic renal 
disease
Kidney
• Acute, subacute, and chronic renal failure
• Severe uncontrolled hypertension
• Renal infarction
Skin
• Livedo reticularis
• Blue toe syndrome
• Ulceration and gangrene
• Purpura
Gastrointestinal system
• Abdominal pain
• Gastrointestinal bleeding
• Bowel ischaemia, infarction, and obstruction
• Pancreatitis, cholecystitis, and abnormal liver tests
• Splenic infarcts
Heart
• Myocardial ischaemia
• Myocardial infarction
Central nervous system
• Transient ischaemic attacks
• Amaurosis fugax
• Altered mental status
• Cerebral infarction
• Spinal cord infarction
Eye
• Retinal emboli (Hollenhorst plaques)
Systemic signs
• Fever
• Weight loss
• Malaise
• Myalgia
• Anorexia
n Skin lesions GI tract CNS Retinal emboli Eosinophilia
Fine4 221 75 (35%) 21 (10%) 0 14 (6%) 22 (73%)
Lye5 129 55 (43%) 16 (10%) 15 (12%) 12 (10%) 57 (71%)
Thadhani8 52 26 (50%) 15 (29%) 12 (23%) 13 (25%) 11 (22%)
Belenfant10 67 60 (90%) 22 (33%) 3 (4%) 15 (22%) 39 (59%)
Scolari27 354 266 (75%) 43 (12%) 35 (10%) 24 (7%) 238 (67%)
GI=gastrointestinal. CNS=central nervous system.
Table 2: Clinical ﬁ ndings in atheroembolic renal disease
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thyroid, and virtually any organ has been reported4,17 
(ﬁ gure 5). Finally, several non-speciﬁ c ﬁ ndings can 
accompany the course of atheroembolic renal disease, 
such as fever, weight loss, myalgias, and headache, 
suggesting the systemic nature of the disease.4,8–12,20,21
Laboratory ﬁ ndings
Laboratory test ﬁ ndings are non-speciﬁ c, such as anaemia, 
leukocytosis, thrombocytopenia, and raised concentrations 
of inﬂ ammatory markers (ESR or C-reactive protein). 
Results of urinalysis are typically benign, with few cells 
and a minimum amount of proteinuria—a ﬁ nding 
consistent with ischaemic damage.4,4,8–12 Nephrotic-range 
proteinuria has been described11,68,69 in a few patients with 
superimposed biopsy-proven focal glomerulosclerosis or 
diabetic nephropathy. Eosinophilia is an abnormal 
laboratory ﬁ nding that frequently occurs during the acute 
phase of the disease, thereby showing immunological 
activation at the surface of the exposed emboli.8–12 In a 
previous review, Kasinath and co-workers70 described 
eosinophilia in 80% of cases of atheroembolic renal 
disease. Eosinophilia was typically transient, ranging from 
6% to 18% in a recent study.70 67% of 354 patients had an 
eosinophil count higher than 500 cells per μL, conﬁ rming 
that eosinophilia can help establish the diagnosis.27 
Other features can include hypocomplementaemia,71 
which has been reported in 39% of patients in one study.5 
However, this ﬁ nding was not consistent with results of 
other studies.8–12 Abnormal laboratory ﬁ ndings can 
implicate speciﬁ c organs: increased concentrations of 
hepatic enzymes suggest liver disease, and raised amylase 
and lipase concentrations pancreatic disease; raised 
creatinine phosphokinase concentration are suggestive 
of myositis, and increased serum aspartate amino-
transferase and lactate dehydrogenase concentrations are 
suggestive of renal infarction.4,10,11 Finally, a few studies9,27,72 
reported proportions of cholesterolaemia in patients with 
atheroembolic renal disease, with total cholesterol higher 
than 5·2 mmol/L ranging from 23% to 27%, and 64%.
Diagnosis
Because atheroembolisation is ubiquitous, atheroembolic 
renal disease can mimic several diﬀ erent clinical 
syndromes.21,73 Knowledge of the risk factors and 
A B C
D E F
G H
Figure 3: Skin lesions in atheroembolic renal disease
Blue toe syndrome of variable severity (A–G); and purpuric lesions (H).
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recognition of the variable clinical presentations can 
heighten the likelihood of making a premortem 
diagnosis.8–12,27 The typical patient at risk is a man older 
than age 60 years with known atherosclerotic disease 
presenting with a clinical triad of a precipitating event, 
acute or subacute renal failure, and typical skin ﬁ ndings. 
Presence of eosinophilia should raise the level of 
suspicion. Renal biopsy is regarded as the deﬁ nitive 
method for diagnosis. Renal samples yield a positive 
diagnosis in more than 75% of patients with acute or 
subacute renal failure.74 However, taking a renal biopsy 
sample is not always feasible, especially in sick patients. 
Taking a biopsy sample of skin lesions, a straightforward, 
and relatively non-invasive procedure, has a high 
diagnostic yield approaching 92%.41 Feet and lower legs 
are also the best sites for biopsy.74,75 Occasionally, 
histological conﬁ rmation can be made from biopsy 
samples from less likely target organs, such as 
gastrointestinal tissues.24 
Tissue biopsy sampling is not necessary when 
cholesterol crystals are seen in the retinal vessels 
(Hollenhorst plaques), which can be identiﬁ ed in 10–25% 
of cases.8–12 For this reason, fundoscopy examination 
should never be omitted. Diagnosis by tissue sample is 
not needed in the presence of the classic triad. For patients 
with the classic triad, atheroembolic renal disease can be 
diagnosed solely on a clinical basis.8–12,27 Thus, renal biopsy 
sampling can be avoided in some patients. Conversely, 
A C 
E 
B 
D F 
50 μM
50 μM 50 μM 50 μM
100 μM 100 μM
Figure 5: Cholesterol crystal in extrarenal sites 
Spleen (A); prostate (B); bladder (C); stomach (D); ileum (E); and lymph node (F).
Figure 4: Retinal cholesterol crystal emboli
A B 
Seminar
www.thelancet.com   Published Online April 9, 2010   DOI:10.1016/SO140-6736(09)62073-0 7
renal biopsy is crucial for diagnosis of cases with chronic, 
smouldering forms of this disease, which are frequently 
spontaneous and usually develop in the absence of evident 
extrarenal signs11,24,27 (panel 3 and table 3). 
Diﬀ erential diagnoses are contrast nephropathy, small-
vessel vasculitis, drug-induced interstitial nephritis, and 
subacute bacterial endocarditis. In contrast nephropathy, 
the rise in plasma creatinine concentrations happens 
immediately after the radiographic study, and the course 
is diﬀ erent—creatinine concentration peaks within a 
few days after exposure and returns to or near baseline 
after 10–14 days.11,20,21,24 Extrarenal emboli, if present, 
enable diagnosis of atheroembolic renal disease. The 
disease can be distinguished from systemic vasculitis by 
urinalysis, typically characterised by the absence of 
proteins and blood cells in atheroembolic renal disease 
as opposed to the nephritic sediment of vasculitis, and 
by an autoimmune screening including antineutrophil 
cytoplasmic antibodies testing.11,24 The temporal relation 
between use of an oﬀ ending drug and occurrence of 
fever, skin rash, eosinophilia, and acute renal failure 
strongly suggests acute tubulointerstitial nephritis, a 
diagnosis that should be conﬁ rmed by renal biopsy. 
Presence of subacute bacterial endocarditis needs to be 
ruled out, especially if hypocomplementaemia is present. 
Signs of systemic infection and echocardiographic 
ﬁ ndings exclude atheroembolic renal disease.
Embolic disease in renal allografts
Atheroembolic renal disease in renal allografts is rare, 
with a frequency ranging from 0·39% to 0·47%.76,77 So far, 
only 45 cases have been reported—too few to deﬁ ne the 
natural history of the disorder.76–85 Such disease is probably 
underestimated because of the use of small needles for 
taking biopsy samples and sampling error. Atheroemboli 
causing injury to the renal allograft can arise from either 
the donor or the recipient vessels. Two distinct clinical 
presentations have been described. The ﬁ rst is an early 
atheroembolic renal disease, with emboli frequently 
released from the donor’s arteries before or during organ 
harvesting. More rarely, early embolisation originates 
from the recipient’s atheromatous vessels during the 
anastomosis. The early form is usually associated with 
primary non-function, and the embolic disease is 
conﬁ ned to the allograft. The second form is a late clinical 
presentation, which can arise years after transplantation 
in stable grafts. In this case, emboli originate from the 
recipient’s vessels. The disease is usually associated with 
recipitating factors, and in some cases shows features of 
a systemic disorder. 
Renal outcomes of early and late atheroembolic disease 
seem to diﬀ er. Graft loss is frequently associated with 
early disease, in which the emboli originate from the 
donor. Prognosis can be especially poor in the setting of 
primary non-function. Conversely, late manifestations 
usually have a good outcome, with graft recovery in most 
cases.11,76–78 The reason for this diﬀ erence could be 
attributable to extensive embolisation in an atherosclerotic 
donor during organ procurement. Because the tendency 
to accept donors and recipients older than age 60 years 
and to use marginal donors with advanced atherosclerosis 
has increased, atheroembolic renal disease in renal 
allografts will probably be encountered more often than 
previously. To reduce the risk of atheroemboli, an accurate 
assessment of organ donors should be done. At the time 
of organ procurement, manipulation of the aorta should 
be kept to a minimum, mobilising the kidneys without 
cross-clamping the aorta, as done for living-related 
donors. Finally, the number of invasive vascular work-up 
procedures should be kept to a minimum.11,77
Treatment
For patients with atheroembolic renal disease, the aim of 
treatment is to restrict the extent of ischaemic damage 
and prevent recurrent embolisation. No deﬁ nitive 
treatment has been established. Therapeutic measures are 
mostly preventive and supportive.8–12,24–27 Mainstays of 
Panel 3: Diagnostic criteria for atheroembolic renal disease
1 Patient at risk
• Men older than 60 years
• Longstanding hypertension
• Tobacco use
• Diﬀ use atherosclerotic disease
2 Presence of classic triad
• Exposure to precipitating factor
• Acute or subacute renal failure
• Peripheral signs of embolisations (eg, blue toe syndrome)
3 Gastrointestinal or neurological eﬀ ects and eosinophilia
• Should raise the level of suspicion
4 Histological conﬁ rmation
• Pathological specimens obtained from the kidney, skin, or 
muscle
• Skin biopsy sample
• Simple, low-invasive procedure with high diagnostic yield
• Tissue biopsy sample not necessary in presence of retinal 
emboli
• Tissue sample not needed in presence of classic triad
• Renal biopsy is crucial to diagnosis of chronic forms of 
atheroembolic renal disease
n Biopsy sample Clinical Postmortem
Kidney Skin Muscle GI tract Other
Fine4 221 15 (7%) 18 (8%) 18 (8%) 5 (2%) 13 (6%) 0 152 (69%)
Thadhani8 52 16 (31%) 9 (17%) 11 (21%) 0 0 5 (9%) 11 (22%)
Belenfant10 69 24 (36%) 15 (22%) 0 12 (18%) 0 16 (24%)* 0
Scolari27 354 63 (18%) 13 (37%) 0 4 (1%) 0 14 (42%)* 7 (2%)
*Clinical diagnosis was conﬁ rmed by retinal emboli in some patients. GI=gastrointestinal.
Table 3: Diagnosis of atheroembolic renal disease
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preventive treatment are based on restriction of  exposure 
to precipitating factors, such as withdrawal of anticoagulant 
therapy after carefully considering the pros and cons of 
these drugs, and avoidance of any additional radiological 
or aortic surgery procedure. Medical intervention in 
established cases is mostly for symptom management, 
and should aim to provide optimum treatment of 
associated hypertension and cardiac and renal failure. 
Cardiac dysfunction and hypertension should be 
aggressively treated. In some cases, renal replacement 
therapy is needed for uraemia and ﬂ uid balance control in 
patients that are unresponsive to high-dose diuretic 
therapy.10–12,24,27,74 The optimum type of dialysis is not known. 
Both peritoneal dialysis and haemodialysis have been 
used.10,11,86,87 Peritoneal dialysis might improve the chances 
of renal recovery because it does not need anticoagulation. 
In the absence of intestinal ischaemia and malnutrition, 
peritoneal dialysis should be the preferred treatment 
modality. However, haemodialysis without or with only 
minimal anticoagulation is not contraindicated. In most 
severe cases, during the acute phase, adequate nutritional 
support can be provided by parenteral nutrition.10
No clinical trials of treatment for patients with 
atheroembolic renal disease have been done. However, 
results of some studies of steroids and statins suggest 
that they might have a potential role. Possible beneﬁ ts of 
steroids have been reported in small series.88–90 Belenfant 
and co-workers10 used low-dose steroid (0·3 mg/kg) in 
18 patients with relapsing disease who had improved 
symptoms and nutritional intake.10 Results of other series72 
have shown beneﬁ cial eﬀ ects with high doses of steroids. 
Conversely, other reports4 have shown little or marginal 
beneﬁ t from steroid treatment. In a prospective study27 of 
354 patients with atheroembolic renal disease, steroids 
were not associated with improved renal or patient 
outcomes. Thus, steroid use is still controversial, although 
it could have a role in patients with multi-system 
involvement, recurrent and progressive disease, and 
systemic inﬂ ammation. 
Interest has grown in the potential protective role of 
statins. Occasional cases of atheroembolic renal disease 
have responded to statins.91 In a prognostic study,12 patients 
assigned statin therapy had a lowered risk of development 
of endstage renal disease. A large prospective study27 
conﬁ rmed this ﬁ nding. Statins had a beneﬁ cial eﬀ ect 
even when statin therapy was started after diagnosis of 
atheroembolic renal disase. The protective eﬀ ect of statins 
could be attributable to plaque stabilisation and regression 
through lipid-lowering and anti-inﬂ ammatory mech-
anisms. Plaque stabilisation might result in a lowered 
risk for further embolisation. However, the observational 
nature of these data precludes establishment of causality. 
Despite these limitations, use of statins could be justiﬁ able 
(panel 4). Finally, there are isolated reports of successful 
therapy in small numbers of patients given iloprost, 
pentoxifylline, and LDL apheresis. These approaches have 
yet to be tested in controlled studies. Other drugs such as 
antiplatelet agents and low-molecular weight dextran do 
not provide any beneﬁ t.11,24
Surgical removal of the source of emboli could oﬀ er a 
deﬁ nitive treatment option. However, surgical treatment 
is often not feasible and is associated with substantial 
morbidity. A clear embolic source is diﬃ  cult to identify. 
Additionally, patients are frequently too weak for surgery. 
Finally, the necessary aortic clamping during surgery 
would induce major risk for recurrence. A surgical 
approach was assessed by Keen and colleagues92 in a 
prospective study of 100 patients. They concluded that 
surgery can be an option when the emboli source is 
located in the infrarenal aorta. If supra-renal aorta is 
implicated, morbidity and mortality is increased because 
of the risk for visceral and renal atheroembolisation. 
Thus, surgical intervention should be regarded as a rescue 
therapy, and restricted to life-threatening situations. To 
eliminate the embolic source, percutaneous transluminal 
angioplasty and stent placement have been undertaken in 
a few patients with aortoiliac and femoral artery sources 
of embolisation.93,94 These endovascular procedures could 
also be associated with a high risk of further embolisation, 
Panel 4: Treatment of atheroembolic renal disease
• Major goal
• Restrict extent of the ischaemic damage 
• Prevent recurrent embolisation
• No deﬁ nitive treatment has been established
• Therapeutic modalities are mostly preventive and 
supportive
• Preventive treatment aims to avoid further precipitating 
factors
• Withdrawal of anticoagulant therapy
• Avoid any new radiological or aortic surgery procedure
• Medical intervention
• Mostly symptomatic
• Aggressive treatment of associated hypertension and 
cardiac and renal failure
• Optimum type of dialysis (peritoneal dialysis vs 
haemodialysis) unknown
• Adequate nutritional support when needed
• Steroids in patients with multisystem involvement 
and recurrent, progressive disease
• Statins should be oﬀ ered to all patients with 
atheroembolic renal disease
n Renal failure 
needing dialysis
Recovery of dialysis-
dependent renal failure
Maintainence dialysis 
(end of follow-up)
1-year 
mortality
Fine4 221 62 (28%) 13 (21%) 0 179 (81%)
Lye5 129 52 (40%) 13 (26%) 0 83 (64%)
Thadhani8 52 23 (44%) 7 (32%) 0 45 (87%)
Belenfant10 67 41 (61%) 16 (39%) 23 (35%) 9 (13%)
Scolari27 354 11 (33%) 33 (28%) 88 (25%) 60 (17%)
Table 4: Renal and patients outcome in atheroembolic renal disease
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possibly occurring as a consequence of vessel injury 
caused by catheters and guide wires within the aorta (type 
1 embolisation) or by active plaque disruption during 
balloon dilation or stenting (type 2 embolisation).95 
Deﬁ nitive recommendations for use of this approach 
cannot yet be made.
Primary prevention of atheroembolic renal disease is 
important, restricting indications for angiography and 
surgical procedures in atherosclerotic patients. Non-
invasive diagnostic methods, such as MR angiography or 
computer-assisted tomographic angiography, could in 
part obviate the risk for catheter-induced embolisation. 
During endovascular procedures, use of proper and 
cautious techniques, including a so-called no touch 
technique avoiding direct trauma of the catheter tip to 
the atheromatous vessel wall might reduce risk of 
embolisation. Finally, the potential application of embolic 
protection devices, which removes atheromatous debris, 
could help keep risk of embolisation to a minimum.
Outcomes
Renal survival
Few outcome studies have been done in patients with 
atheroembolic renal disease. Renal prognosis is poor. Lye 
and co-workers5 reported that 40% of 129 patients needed 
dialysis, of whom only 21% recovered suﬃ  cient renal 
function to stop dialysis. In a series, Thadhani and 
colleagues8 reported that 44% of 52 patients underwent 
dialysis. Belenfant and co-workers10 reported that dialysis 
was needed in 61% of 67 patients, with 13 patients 
regaining suﬃ  cient renal function to be free of dialysis. 
In a prospective study,12 37% of 95 patients needed dialysis, 
14 recovered suﬃ  cient renal function to stop dialysis, and 
23 remained dialysis dependent (24%; table 4). The most 
important predictors of endstage renal disease needing 
permanent dialysis therapy were pre-existing chronic 
renal insuﬃ  ciency and longstanding hypertension. 
Another major ﬁ nding was a protective beneﬁ t of 
statins—patients given statin treatment had a signiﬁ cantly 
lower risk for development of end-stage renal disease 
than did those not given statins.12
Patient survival
Atheroembolic renal disease is generally associated with 
high mortality. An 81% mortality rate was reported by 
Fine and co-workers at 1 year.4 Lye and colleagues5 reported 
a 64% mortality rate at 1 year. The major cause of death 
was cardiovascular. A favourable clinical outcome, with a 
1-year mortality rate of 13%, was reported by Belenfant,10 
with an aggressive therapeutic approach. The protocol 
was based on avoidance of anticoagulation and aortic 
manipulating procedures, good control of hypertension 
and heart failure, dialytic therapy, and adequate nutritional 
support. Beneﬁ ts of similar supportive care were 
conﬁ rmed in a prospective study27 of 354 patients, with an 
83% 1-year patient-survival rate (table 4). Predictors of 
increased risk for death were diabetes and heart failure, 
baseline levels of renal function, acute or subacute renal 
failure, and development of extrarenal manifestations, 
especially aﬀ ecting the gastrointestinal tract (relative risk 
[RR] 2·57, 95% CI 1·69–3·93). Finally, previous statin use 
was associated with improved patient survival (RR 0·44, 
0·28–0·67). Notably, the same predictors were associated 
with an increased risk for endstage renal disease, 
suggesting a common underlying mechanism for renal 
and cardiovascular events.27
Future research
Atheroembolic renal disease has become a recognisable 
cause of renal failure. However, its incidence in patients 
at risk remains unknown, and diagnosis depends on 
how much experience centres have had with this 
disease. Ideally, a systematic search for signs and 
symptoms of the dis ease in populations undergoing 
aortic procedures would provide information to answer 
this important question. In terms of prognosis of 
established cases, avoid ance of known precipitating 
factors and individualised supportive measures could 
substantially improve clinical out come.96,97 However, the 
disorder greatly aﬀ ects patient and renal survival, and 
further research is urgently needed to alter its clinical 
course. Three diﬀ erent areas of clinical investigation 
need to be explored. 
The ﬁ rst is the potential beneﬁ t of speciﬁ c therapies, 
such as steroids and statins. A reactive inﬂ ammation 
around the crystals is suggested by eosinophilia, a 
cytokine-mediated occurrence,98 and has a role in causing 
or worsening ischaemia. However, anti-inﬂ ammatory 
beneﬁ ts might be counterbalanced by harmful eﬀ ects of 
steroids on the cardiovascular system. For this reason, 
beneﬁ ts and harms of steroid treatment should be tested 
in clinical trials. The protective role of statins12,27 should 
also be conﬁ rmed by intervention studies. Atheroembolic 
renal disease alone represents an indication for standard 
statin therapy. Intensive statin therapy seems to provide 
more cardiovascular protection than does standard 
therapy in patients with coronary disease,99,100 and whether 
this eﬀ ect applies to patients with atheroembolic renal 
disease needs to be tested.
The second area of research is the modality of renal 
replacement therapy in patients needing dialysis. Clinical 
trials are necessary to test whether standard haemodialysis 
needing anticoagulation is associated with worse patient 
and renal outcomes than is peritoneal dialysis. Last, the 
prognostic eﬀ ect of antiembolic devices during 
endovascular procedures on the evolution of atheroembolic 
renal disease is unknown. This approach is the standard 
of care during carotid artery stenting because it reduces 
procedure-related embolic strokes.101 Such protection 
devices have also been used during renal artery stenting 
with promising results.102 Insuﬃ  cient information is 
available to test the pros and cons of a broadened use to 
reduce short-term and long-term atheroembolic com-
plications of endovascular procedures. 
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